- All
- November 19, 2026
- November 20, 2026
- November 21, 2026
- All
- 5th‑Floor Grand Ballroom
- S101
- S102
- S103
- S105
- S106
- S107
- S109
- S110
- S111
- S201
- S202
- S203
- S204
- S205
- S206
- S207
- V11
- V22
- V23
- V24
- V25
- InterContinental Ballroom 1
- All
- Plenary Session
- Oncology
- Minimally Invasive Surgery
- Stones
- Incontinence
- Robotic Surgery
- Clinical Research
- Basic and Translational Science
- Female Urology
- Andrology
- Nursing
- Infection
- Renal Transplantation
- Laser Surgery
- Community Urology
- Reconstructive Surgery
- Adrenals
- Pediatric Urology
- Smart Surgery
- Urological Engineering
- Special Session
- Prostate Cancer Pathfinders: Evidence into Action
- Prostate Neoplasms Session
- Benign Diseases Diagnosis & Treatment Session
- Urolithiasis Standardized Care Project
- Discovering Urological Frontiers
- Urology & Prostate
- Rising Leaders Urology
- Urologic Oncology Session
- Training Program for Urological Department
- Precision Care in Urologic Oncology
- Uro-Oncology Leadership & Innovation Forum
- Remote Session: Normalized Surgical Practice
- RCC Immunotherapy Session
- Intelligent Leadership in Prostate Care
- Bladder Cancer Session
- MP + SP in URO Seminar
- Benign Prostatic Hyperplasia Session
- Ingenuity Exploration
- Renal Cell Carcinoma Session
- Prostate Cancer Session
November 19, 2026
V23
| 1 | 13:30-13:35 |
Opening Remarks |
|
|||||
| 1 | 13:35-13:45 |
Sharing of rosette suture technique in partial nephrectomy |
|
||||||||||||||||||||
| 2 | 13:45-13:55 |
Application of split robot in prostate surgery |
|
||||||||||||||||||||
| 3 | 13:55-14:05 |
Innovative technology and development of urinary tract reconstruction |
|
||||||||||||||||||||
| 4 | 14:05-14:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 14:30-14:40 |
Modified single-port robotic radical prostatectomy(pf-ssRARP) |
|
|||||||||||||||||||||||
| 2 | 14:40-14:50 |
Exploration and practice of application from single-port Laparoscopy to robot-assisted single-port Laparoscopy (MR-LESS) in urology |
|
|||||||||||||||||||||||
| 3 | 14:50-15:00 |
Urinary diversion for the patient’s quality of life |
|
|||||||||||||||||||||||
| 4 | 15:00-15:25 |
Discussion |
|
|||||||||||||||||||||||
| 1 | 15:25-15:30 |
Summary |
|
|||||
| 1 | 16:10-16:20 |
Opening Remarks |
|
|||||||||||
| 1 | 16:20-16:40 |
Advancing Through Evidence, Balancing with Precision: Research Progress and Clinical Decision-Making in First-Line Targeted Therapy Plus Immunotherapy for Advanced ccRCC |
|
|||||
| 2 | 16:40-17:00 |
Anlotinib plus Benmelstibart as First-Line Therapy for Renal Cell Carcinoma: Safety Management and Dose Optimization |
|
|||||
| 1 | 17:00-18:00 |
Discussion： Topic 1 Topic 2 |
|
|||||||||||||||||||||||||||||||||||||||||
| 1 | 18:00-18:10 |
Summary |
|
|||||||||||